Literature DB >> 10551321

Rare-type mutations of MMAC1 tumor suppressor gene in human glioma cell lines and their tumors of origin.

S J Zhang1, S Endo, T Ichikawa, J Yoshimura, K Onda, R Tanaka, K Washiyama, T Kumanishi.   

Abstract

A total of 10 glioma cell lines were examined to evaluate the status of the MMAC1 gene, a candidate tumor suppressor gene. Six cell lines showed mutations with presumed loss of heterozygosity and 1 cell line showed no mRNA expression. The 6 mutations consisted of 3 3-bp deletions (codons 17, 101 or 199), 1 missense mutation (codon 252) and 2 truncation mutations (1 nonsense mutation at codon 233 and 12-bp insertion at codon 241). Among them, the 3-bp deletions, which are a rare type of mutation in MMAC1 gene, were located in the N-terminal half (codons 1-212) of the coding region, which is considered important in MMAC1 function. The missense mutation was located unusually in the C-terminal half (codons 212-403), but it was in a small region in which some other reported missense mutations are clustered. Thus, these 4 mutations were suggested to have functional effects on the MMAC1 activity, like the other 2 mutations with predicted protein truncations. By sequence analysis of cDNA clones, we confirmed that all the mutations including these 4 rare ones were in the MMAC1 gene, not in the PTH2 pseudogene. In 2 cases, we also examined the primary glioma tissues from which the cell lines had been derived and found the same mutations as in the cell lines in both cases. This suggested that the mutations in these cell lines were derived from the primary glioma tissues, but not from artifacts arising during long-term in vitro cultivation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551321      PMCID: PMC5926156          DOI: 10.1111/j.1349-7006.1999.tb00838.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


single‐stand conformation polymorphism reverse transcriptase‐polymerase chain reaction loss of heterozygosity
  34 in total

1.  PTEN1 is frequently mutated in primary endometrial carcinomas.

Authors:  D Kong; A Suzuki; T T Zou; A Sakurada; L W Kemp; S Wakatsuki; T Yokoyama; H Yamakawa; T Furukawa; M Sato; N Ohuchi; S Sato; J Yin; S Wang; J M Abraham; R F Souza; K N Smolinski; S J Meltzer; A Horii
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

2.  Alterations of the MMAC1/PTEN gene in lymphoid malignancies.

Authors:  K Grønbaek; J Zeuthen; P Guldberg; E Ralfkiaer; K Hou-Jensen
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

3.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

Authors:  P Cairns; K Okami; S Halachmi; N Halachmi; M Esteller; J G Herman; J Jen; W B Isaacs; G S Bova; D Sidransky
Journal:  Cancer Res       Date:  1997-11-15       Impact factor: 12.701

4.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

5.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

6.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

Authors:  P Guldberg; P thor Straten; A Birck; V Ahrenkiel; A F Kirkin; J Zeuthen
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

7.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

8.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Authors:  D H Teng; R Hu; H Lin; T Davis; D Iliev; C Frye; B Swedlund; K L Hansen; V L Vinson; K L Gumpper; L Ellis; A El-Naggar; M Frazier; S Jasser; L A Langford; J Lee; G B Mills; M A Pershouse; R E Pollack; C Tornos; P Troncoso; W K Yung; G Fujii; A Berson; P A Steck
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

9.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Authors:  B K Rasheed; T T Stenzel; R E McLendon; R Parsons; A H Friedman; H S Friedman; D D Bigner; S H Bigner
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

10.  A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations.

Authors:  S Zhang; S Endo; H Koga; T Ichikawa; X Feng; K Onda; K Washiyama; T Kumanishi
Journal:  Jpn J Cancer Res       Date:  1996-09
View more
  2 in total

1.  Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.

Authors:  Inga Grünewald; Claudia Vollbrecht; Jeannine Meinrath; Moritz F Meyer; Lukas C Heukamp; Uta Drebber; Alexander Quaas; Dirk Beutner; Karl-Bernd Hüttenbrink; Eva Wardelmann; Wolfgang Hartmann; Reinhard Büttner; Margarete Odenthal; Markus Stenner
Journal:  Oncotarget       Date:  2015-07-20

2.  Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.

Authors:  Ramon Martinez; Veit Rohde; Gabriele Schackert
Journal:  J Neurooncol       Date:  2009-07-31       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.